Efficacy and safety of Xihuang pill for gastric cancer

Abstract

Background: Xihuang pill has been widely applied as a promising adjunctive drug for gastric cance. However, the exact effects and safety of Xihuang pill have yet to be systematically investigated. We aimed to summarize the effificacy and safety of Xihuang pill for the treatment of advanced GC through the meta-analysis, in order to provide scientific reference for the design of future clinical trials. Methods: The protocol followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. Relevant randomized controlled trials were searched from PubMed, the Cochrane Library, Embase, the China National Knowledge Infrastructure, Wanfang Database, Chinese Science and echnology Periodical Database, and Chinese Biomedical Literature Database. Papers in English or Chinese published from their inception to October 2020 will be included without any restrictions. Cochrane Risk of Bias tool will be used to assess the risk of bias of included studies. The RevMan 5.4 and Stata 16.0 software will be applied for statistical analyses. Statistical heterogeneity will be computed by I 2 tests. Sensitivity analysis will be conducted to evaluate the stability of the results. The publication bias will be evaluated by funnel plots and Egger test. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluate system. Results: The results of our research will be published in a peer-reviewed journal. Conclusion: The conclusion of this study will provide helpful evidence of the effect and safety of Xihuang pill for the treatment of GC in clinical practice. OSF registration number: 10.17605/OSF.IO/VFJAK.

The prospect of Xihuang pill in the treatment of cancers

“…We identified 78 studies on clinical aspects of Xihuang pills/capsules in treating cancer, including 11 specific types of cancer and multiple types of cancer. Twenty-five studies reported in treating breast cancer (32%) [ [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] ] ( Table 2 ), 14 lung cancer (17.9%) [ 6 , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] ] ( Table 3 ), 11 cervical cancer (14.1%) [ 5 , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] ] ( Table 4 ), 6 esophagus cancer (7.6%) [ [60] , [61] , [62] , [63] , [64] , [65] ] ( Table 5 ), 5 liver cancer (6.4%) [8,66 = 69], ( Table 6 ), 3 pancreatic cancer (3.8%) [ [66] , [67] , [68] ] ( ...…”

Study on the Potential Molecular Mechanism of Xihuang Pill in the Treatment of Pancreatic Cancer Based on Network Pharmacology and Bioinformatics

“…XHP has therapeutic effects on diverse tumors. It is widely used as a supplementary drug in the treatment of a variety of malignant tumors in China, such as pancreatic cancer [ 6 ], lung cancer [ 27 ], gastric cancer [ 28 ], and breast cancer [ 29 ]. However, the underlying mechanisms of XHP treating cancers remain unclear.…”

The traditional Chinese medicine and non-small cell lung cancer: from a gut microbiome perspective

“…(Zhang et al, 2021b). It has been widely used in the treatment of a variety of malignant tumors in clinics in China, including breast cancer, lung cancer, gastric cancer, and other malignant tumors (Wang et al, 2020a;Wang et al, 2021a;Ge et al, 2022). In mice with Lewis lung cancer, Cao et al investigated the anti-lung cancer impact of XHW coupled with anlotinib (LLC).…”

“…Studies indicate links between dysbiosis or disturbance in the microbiome and diseases that not only affect the gut but also organs like the lung, thyroid, brain, cardiac, immune system, etc. ( Tang et al., 2019 ; Hufnagl et al., 2020 ; Knezevic et al., 2020 ; Rutsch et al., 2020 ; Wang et al., 2022a ). The crosstalk between the gut microbiome and distal organs is being increasingly recognized, and host-microbiome interactions are being delineated piece by piece.…”